Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Aspen Technology Inc

Alibaba

British American Tobacco

Cboe Global Markets

Cisco Systems

eBay

McKesson

Altria

Oracle

Polaris

Philip Morris

SEI Investments

T. Rowe Price Group

Optimism about effective vaccines coming soon have sent the market back to record highs, ending the pullback. For the rest of the year, the pandemic is expected to continue getting worse. JPMorgan estimates a 20% to 25% probability of a double-dip recession and a 22% bear market.

The 15 Highest Quality Blue Chips To Buy With Market At All-Time Highs

Home Depot

Microsoft

Target

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walmart

The election is finally over, and investors are euphoric about Pfizer and BioNTech's COVID vaccine candidate. As markets seem to see-saw based on sentiment, quality companies that pay solid dividends are always a great way to go.

Top Dividend Stocks For November

SYDNEY--(BUSINESS WIRE)-- #clinicaltrials--Noxopharm announces pilot study with Bristol Myers Squibb's product

Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference

Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference

Amgen

Anthem

Cigna

As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.

5 Leading Healthcare Stocks Surging On Pent-Up Demand

Citigroup

GlaxoSmithKline

Merck

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR20--BMS Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis.

Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Painful sell-off in BMY.RT yesterday after a confusing Bristol-Myers conference call. The call was really awful because BMY basically said two facilities need to be inspected, one isn't and they aren't scheduled.

Bristol-Myers Squibb Contingent Value Rights: Inclined To Believe There's Still Value

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo Plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic NSCLC

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

The credit mainly lies with the big drugmaker's acquisition of Celgene last year.

How Bristol Myers Squibb Beat Wall Street Estimates in Q3

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q3 2020 Results - Earnings Call Transcript

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.

Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised

When Bristol-Myers Squibb Co. (NYSE: BMY) reported third-quarter 2020 results before markets opened Thursday, the pharmaceutical firm posted adjusted diluted earnings per share (EPS) of $1.63 on revenue of $10.5 billion.

What More Can Bristol-Myers Squibb Do?

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 6.8%

Early Thursday, Bristol-Myers Squibb reported adjusted earnings of $1.63 per share on $10.54 billion in sales for its third quarter ended Sept. 30. In response, BMY stock edged higher.

This Leading Pharma Stock Jumped On Its Third-Quarter Beat And Raise

Bristol Myers (BMY) delivered earnings and revenue surprises of 9.40% and 1.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates

  Shares of Bristol-Myers Squibb (NYSE:BMY) moved higher by 1.4% in pre-market trading after the company reported Q3 results.

Recap: Bristol-Myers Squibb Q3 Earnings

Shares of Bristol Myers Squibb Co. gained 1.9% in premarket trading on Thursday after the drug maker largely beat expectations for the third quarter. The company had earnings of $1.87 billion, or 82 cents per share, in the third quarter of 2020, up from $1.36 billion, or 83 cents per share, in the same quarter a year ago.

Bristol Myers Squibb's stock gains with Eliquis sales jumping 9% during the third quarter

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR20--BMS Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases

Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Third Quarter 2020 Financial Results

Bristol Myers Squibb Reports Third Quarter 2020 Financial Results

AstraZeneca

Eli Lilly

Divided government could be good news for big pharma.

Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today

Bristol-Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Bristol-Myers Squibb (BMY)

Let us take a look at four big drug/biotech companies, REGN, BMY, INCY & ZTS, which are gearing up for their earnings release.

Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More

MyoKardia

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 1

Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period

Transformative deals are a recurring theme for this pharmaceutical industry giant.

News for Bristol-Myers Stock (BMY)